ValuEngine Upgrades Pharmerica Corporation (PMC) to “Buy”

ValuEngine upgraded shares of Pharmerica Corporation (NYSE:PMC) from a hold rating to a buy rating in a research report report published on Tuesday.

PMC has been the topic of a number of other research reports. Zacks Investment Research cut shares of Pharmerica Corporation from a buy rating to a hold rating in a research note on Wednesday, October 4th. KeyCorp cut shares of Pharmerica Corporation to an overweight rating in a research note on Tuesday, August 8th. Credit Suisse Group cut shares of Pharmerica Corporation from an outperform rating to a neutral rating and raised their target price for the stock from $29.00 to $29.25 in a research note on Friday, August 4th. They noted that the move was a valuation call. BidaskClub cut shares of Pharmerica Corporation from a hold rating to a sell rating in a research note on Monday, July 31st. Finally, Barrington Research cut shares of Pharmerica Corporation from an outperform rating to an underperform rating in a research note on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average price target of $30.50.

Shares of Pharmerica Corporation (NYSE:PMC) opened at $29.15 on Tuesday. The company has a market capitalization of $905.56 million, a P/E ratio of 15.24, a P/E/G ratio of 1.27 and a beta of 0.82. The company has a current ratio of 2.57, a quick ratio of 1.79 and a debt-to-equity ratio of 0.75.

Pharmerica Corporation (NYSE:PMC) last released its earnings results on Wednesday, August 2nd. The company reported $0.47 EPS for the quarter, hitting analysts’ consensus estimates of $0.47. Pharmerica Corporation had a net margin of 1.05% and a return on equity of 10.94%. The company had revenue of $592.00 million for the quarter, compared to analysts’ expectations of $592.96 million. During the same quarter last year, the business earned $0.47 EPS. The firm’s revenue was up 13.9% compared to the same quarter last year. equities analysts forecast that Pharmerica Corporation will post 1.92 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This article was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://www.com-unik.info/2017/11/04/valuengine-upgrades-pharmerica-corporation-pmc-to-buy.html.

Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. raised its position in shares of Pharmerica Corporation by 51,604.4% during the first quarter. BlackRock Inc. now owns 3,975,551 shares of the company’s stock valued at $93,027,000 after buying an additional 3,967,862 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Pharmerica Corporation by 0.6% during the second quarter. Dimensional Fund Advisors LP now owns 2,618,313 shares of the company’s stock valued at $68,731,000 after buying an additional 14,399 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Pharmerica Corporation by 5.5% during the second quarter. Vanguard Group Inc. now owns 1,649,704 shares of the company’s stock valued at $43,305,000 after buying an additional 85,838 shares during the last quarter. Boston Partners raised its position in shares of Pharmerica Corporation by 4.4% during the third quarter. Boston Partners now owns 1,436,519 shares of the company’s stock valued at $42,090,000 after buying an additional 60,232 shares during the last quarter. Finally, Victory Capital Management Inc. raised its position in shares of Pharmerica Corporation by 40.1% during the second quarter. Victory Capital Management Inc. now owns 1,294,142 shares of the company’s stock valued at $33,971,000 after buying an additional 370,266 shares during the last quarter. Hedge funds and other institutional investors own 90.86% of the company’s stock.

Pharmerica Corporation Company Profile

To view ValuEngine’s full report, visit ValuEngine’s official website.

What are top analysts saying about Pharmerica Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pharmerica Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit